Eqis Capital Management, Inc. Geron Corp Transaction History

Eqis Capital Management, Inc.

12 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$2.14 - $3.4 $1,566 - $2,488	-732 Reduced 5.15%	13,489 $29,000
Q4 2022 Feb 14, 2023	SELL	$2.03 - $2.42 $38 - $45	-19 Reduced 0.13%	14,221 $34,000
Q3 2022 Oct 24, 2022	SELL	$1.67 - $2.94 $1,300 - $2,290	-779 Reduced 5.19%	14,240 $33,000
Q2 2022 Aug 08, 2022	SELL	$1.19 - $1.65 $1,601 - $2,220	-1,346 Reduced 8.22%	15,019 $23,000
Q1 2022 May 16, 2022	SELL	$0.99 - $1.6 $1,105 - $1,787	-1,117 Reduced 6.39%	16,365 $22,000
Q4 2021 Feb 14, 2022	SELL	$1.22 - $1.72 $1,584 - $2,234	-1,299 Reduced 6.92%	17,482 $21,000
Q3 2021 Nov 12, 2021	BUY	$1.2 - $1.5 $642 - $802	535 Added 2.93%	18,781 $26,000
Q2 2021 Aug 12, 2021	BUY	$1.25 - $1.83 $1,462 - $2,141	1,170 Added 6.85%	18,246 $26,000
Q1 2021 May 14, 2021	BUY	$1.52 - $2.1 $4,593 - $6,346	3,022 Added 21.5%	17,076 $27,000
Q4 2020 Feb 11, 2021	BUY	$1.55 - $2.05 $2,219 - $2,935	1,432 Added 11.35%	14,054 $22,000
Q3 2020 Nov 10, 2020	BUY	$1.59 - $2.19 $3,601 - $4,960	2,265 Added 21.87%	12,622 $22,000
Q2 2020 Aug 10, 2020	BUY	$1.05 - $2.18 $10,874 - $22,578	10,357 New	10,357 $23,000

274

491M

1.87M

690K

Ticker GERN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 377,819,008
Market Cap $1.28B
Description
Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in hemat...

Get notified when there are updates to the investment portfolio of Eqis Capital Management, Inc., based on Form 13F filings with the SEC.

Stay updated on Eqis Capital Management, Inc. with notifications on news.